Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fosaprepitant
Drug ID BADD_D00962
Description Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Indications and Usage For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB06717
KEGG ID D10895
MeSH ID C579707
PubChem ID 135413538
TTD Drug ID Not Available
NDC Product Code 43598-948; 72205-054; 72205-083; 16714-929; 68180-690; 43598-859; 71839-104; 63323-972; 70710-1615; 16729-240; 68001-517; 0781-3497; 68001-421; 16714-120; 69539-181; 72205-026; 60505-6105; 69097-830; 69539-034; 67457-889; 0591-4385
UNII 6L8OF9XRDC
Synonyms fosaprepitant | Emend for injection | fosaprepitant dimeglumine | L 785,298 | L785,298 | L-785,298
Chemical Information
Molecular Formula C23H22F7N4O6P
CAS Registry Number 172673-20-0
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C( C=C4)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Menopausal symptoms21.02.02.002--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Nervous system disorder17.02.10.001--Not Available
Neutrophil count decreased13.01.06.010--
Oedema14.05.06.010; 08.01.07.006--Not Available
Osteoarthritis15.01.04.001--Not Available
Palpitations02.11.04.012--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Polydipsia14.05.02.001; 05.03.03.002--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Sensory disturbance17.02.07.006--Not Available
Skin disorder23.03.03.007--Not Available
Skin lesion23.03.03.010--Not Available
Sneezing22.12.03.024--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stomatitis07.05.06.005--
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Type I hypersensitivity10.01.03.006--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages